
Clinical outcomes in patients with relapsing-remitting multiple sclerosis who switch from natalizumab to delayed-release dimethyl fumarate: A multicenter retrospective observational study (STRATEGY)
Keywords: AE; adverse event; ARR; annualized relapse rate; DMF; dimethyl fumarate; DMT; disease-modifying therapy; HR; hazard ratio; IPTW; inverse probability of treatment weight; JCV; John Cunningham virus; MS; multiple sclerosis; PML; progressive multifocal leuko